PAG
RXRX icon

Private Advisor Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Private Advisor Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Buy
102,447
+35,608
+53% +$119K ﹤0.01% 1975
2026
Q1 		$205K Buy
66,839
+8,967
+15% +$34.7K ﹤0.01% 2449
2025
Q4 		$237K Buy
57,872
+4,849
+9% +$24K ﹤0.01% 2303
2025
Q3 		$259K Sell
53,023
-25,908
-33% -$136K ﹤0.01% 2172
2025
Q2 		$399K Buy
78,931
+34,624
+78% +$170K ﹤0.01% 1810
2025
Q1 		$234K Buy
44,307
+12,880
+41% +$93.9K ﹤0.01% 2013
2024
Q4 		$212K Buy
31,427
+16,008
+104% +$108K ﹤0.01% 2058
2024
Q3 		$102K Buy
15,419
+3,432
+29% +$24.6K ﹤0.01% 2310
2024
Q2 		$89.9K Buy
+11,987
New +$105K ﹤0.01% 2241
2023
Q4 		– Sell
-10,326
Closed -$79K – 2465
2023
Q3 		$79K Buy
+10,326
New +$103K ﹤0.01% 1990

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Private Advisor Group's RXRX Position: Q2 2026 in Review

Private Advisor Group increased its Recursion Pharmaceuticals (RXRX) stake by 53% in Q2 2026, buying an estimated $119K and bringing the position to 102,447 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

Private Advisor Group first reported a position in RXRX in Q3 2023 and has held it in 10 quarters since. The position peaked at $399K in Q2 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Private Advisor Group held 102,447 shares of Recursion Pharmaceuticals worth $376K as of Q2 2026.
  • Private Advisor Group bought 35,608 Recursion Pharmaceuticals shares in Q2 2026, an estimated $119K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #1975 holding.
  • Private Advisor Group first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Private Advisor Group's Recursion Pharmaceuticals position peaked at $399K in Q2 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.